

1646



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/625,573	
	Filing Date	July 25, 2000	
	First Named Inventor	Charo, Israel R.	
	Art Unit	1646	
	Examiner Name	Christopher J. Nichols	
Total Number of Pages in This Submission	3	Attorney Docket Number	02307K-085040US

TECH CENTER 1600 1500
APR 22 2003

RECEIVED

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response to Restriction Requirement <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP William Schmonsees Reg. No. 31,796
Signature	
Date	April 14, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: 4/14/03			
Typed or printed	Kristi Coplin		
Signature		Date	April 14, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 02307K-085040US
Client Ref. No.: 93-239-2

Assistant Commissioner for Patents
Box: AMENDMENT - NO FEE
Washington, D.C. 20231

On 4/14/03

TOWNSEND and TOWNSEND and CREW LLP

By: Bruce Cope

PATENT

RECEIVED

APR 22 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Israel F. Charo

Application No.: 09/625,573

Filed: July 25, 2000

For: MAMMALIAN MONOCYTE
CHEMOATTRACTANT PROTEIN
RECEPTORS

Examiner: Christopher J. Nichols

Art Unit: 1646

AMENDMENT

Assistant Commissioner for Patents
BOX: Amendment - NO FEE
Washington, D.C. 20231

Sir:

Responsive to the Office action mailed March 13, 2003, Applicants hereby submit the following election without traverse.

THE REQUIREMENT:

Claims 2-19 are pending. The Action restricts the invention into four groups as follows:

- I. Claims 2-19 (each in part), drawn to a method of making an antibody which specifically binds MCP-1 receptor polypeptide wherein the polypeptide is SEQ ID NO: 2, classified in class 424, subclass 130.1, for example.
- II. Claims 2-19 (each in part), drawn to a method of making an antibody which specifically binds MCP-1 receptor polypeptide wherein the polypeptide is SEQ ID NO: 4, classified in class 424, subclass 130.1, for example.

Serial No.: 09/625,573
02307K-085040US
April 14, 2003


- III. Claims 2-4 and 9-19 (each in part), drawn to a method of making an antibody which specifically binds MCP-1 receptor polypeptide wherein the polypeptide is a polypeptide encoded by an isolated nucleic acid comprising residues 40 through 1161 of the DNA sequence of SEQ ID NO: 1, classified in class 424, subclass 130.1, for example.
- IV. Claims 2-4 and 9-19 (each in part), drawn to a method of making an antibody which specifically binds MCP-1 receptor polypeptide wherein the polypeptide is a polypeptide encoded by an isolated nucleic acid comprising residues 81 through 1160 of the DNA sequence of SEQ ID NO: 3, classified in class 424, subclass 130.1, for example.

Applicants elect to prosecute the invention of Group II, Claims 2-19 (each in part), drawn to a method of making an antibody which specifically binds MCP-1 receptor polypeptide wherein the polypeptide is SEQ ID NO: 4. Applicants also point out that claims 2-12, 18 and 19 are directed to antibodies *per se*, claims 13-15 to cell lines, and claim 17 to a composition; only claim 16 is drawn to a method of making antibodies. Applicants presume that the restriction applies to all claims, not to just the method of making claim.

This election is made with traverse. Applicants request reconsideration and redefinition of the restriction requirement on the grounds that the antibodies of Groups II and IV are the same, as are the antibodies of Groups I and III. The nucleic acids recited in Groups III and IV encode the polypeptides of Groups I and II, respectively. Applicants request that Groups I and III be combined into one group and Groups II and IV into another.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



William Schmonsees
Reg. No. 31,796

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400 / Fax: 415-576-0300
WS:klc
PA 3296238 v1